Literature DB >> 10449487

Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis.

L Saiman1, J L Burns, S Whittier, J Krzewinski, S A Marshall, R N Jones.   

Abstract

The development of multidrug-resistant Pseudomonas aeruginosa in patients with cystic fibrosis (CF) is most likely a consequence of increasing life expectancy and more prolonged exposure to antibiotics. The optimal method for antibiotic susceptibility testing of CF strains, particularly mucoid P. aeruginosa strains, is unknown. Antimicrobial susceptibilities of 48 CF strains (25 mucoid) and 50 non-CF strains to 12 anti-Pseudomonas agents were tested by both agar dilution and commercially custom-prepared broth microdilution plates (PML Microbiologicals, Portland, Oreg.) in three laboratories simultaneously to determine if broth microdilution could substitute for agar dilution as the reference method in subsequent studies. Comparison of MICs generated by agar dilution and broth microdilution demonstrated correlation coefficients (r) exceeding 0.85 for all agents tested; correlation was excellent for aminoglycosides (r >/= 0.92) and very good for beta-lactam agents including agents paired with a beta-lactamase inhibitor (r >/= 0.87) and for ciprofloxacin (r = 0.86). Correlation was not improved by 48-h readings, but correlation between 24- and 48-h readings ranged between 0.91 and 0.98 for both methods. Interlaboratory variations were minimal, as the percentage of acceptable variations was 94% for both methods, and serious discords were infrequent (<2% of comparisons). However, CF strains were more likely to have serious discords than were non-CF strains (P < 0. 0001), although mucoid strains were not more likely to have serious discords than were nonmucoid strains. In this study, MICs determined by custom-prepared broth microdilution compared favorably with MICs determined by agar dilution. Thus, this broth microdilution assay can serve as a reference method and facilitate future studies to determine the optimal method for antibiotic susceptibility testing of CF strains.

Entities:  

Mesh:

Year:  1999        PMID: 10449487      PMCID: PMC85429     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Mixed morphotype susceptibility testing of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  W M Dunne; M J Chusid
Journal:  Diagn Microbiol Infect Dis       Date:  1987-02       Impact factor: 2.803

2.  Mixed-morphotype broth microdilution susceptibility testing of Pseudomonas aeruginosa from cystic fibrosis patients.

Authors:  K G Van Horn
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

Review 3.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

4.  Evaluation of E-Test for determination of antimicrobial MICs for Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  E F Marley; C Mohla; J M Campos
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

5.  Accuracy and cost of antibiotic susceptibility testing of mixed morphotypes of Pseudomonas aeruginosa.

Authors:  G L Morlin; D L Hedges; A L Smith; J L Burns
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

6.  The changing epidemiology of cystic fibrosis.

Authors:  S C FitzSimmons
Journal:  J Pediatr       Date:  1993-01       Impact factor: 4.406

7.  Antimicrobial susceptibilities of rough, smooth, and mucoid colony types of Pseudomonas isolated from cystic fibrosis patients.

Authors:  B A Maybury; J Blessing-Moore; S A deWit; N J Lewiston; A S Yeager
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

8.  Microbiology of sputum from patients at cystic fibrosis centers in the United States.

Authors:  J L Burns; J Emerson; J R Stapp; D L Yim; J Krzewinski; L Louden; B W Ramsey; C R Clausen
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079

9.  Pseudomonas aeruginosa: biology, mechanisms of virulence, epidemiology.

Authors:  M L Vasil
Journal:  J Pediatr       Date:  1986-05       Impact factor: 6.314

10.  Biotinylated DNA probes for exotoxin A and pilin genes in the differentiation of Pseudomonas aeruginosa strains.

Authors:  M Samadpour; S L Moseley; S Lory
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 11.677

View more
  16 in total

1.  Compliance of clinical microbiology laboratories in the United States with current recommendations for processing respiratory tract specimens from patients with cystic fibrosis.

Authors:  Juyan Zhou; Elizabeth Garber; Manisha Desai; Lisa Saiman
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

2.  Accuracies of beta-lactam susceptibility test results for Pseudomonas aeruginosa with four automated systems (BD Phoenix, MicroScan WalkAway, Vitek, and Vitek 2).

Authors:  Stefan Juretschko; Vincent J Labombardi; Stephen A Lerner; Paul C Schreckenberger
Journal:  J Clin Microbiol       Date:  2007-01-17       Impact factor: 5.948

3.  Validation of Vitek 2 nonfermenting gram-negative cards and Vitek 2 version 4.02 software for identification and antimicrobial susceptibility testing of nonfermenting gram-negative rods from patients with cystic fibrosis.

Authors:  Ines Otto-Karg; Stefanie Jandl; Tobias Müller; Beate Stirzel; Matthias Frosch; Helge Hebestreit; Marianne Abele-Horn
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

4.  Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.

Authors:  Eric E Smith; Danielle G Buckley; Zaining Wu; Channakhone Saenphimmachak; Lucas R Hoffman; David A D'Argenio; Samuel I Miller; Bonnie W Ramsey; David P Speert; Samuel M Moskowitz; Jane L Burns; Rajinder Kaul; Maynard V Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-10       Impact factor: 11.205

5.  Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.

Authors:  Samuel M Moskowitz; Elizabeth Garber; Yunhua Chen; Sarah A Clock; Setareh Tabibi; Amanda K Miller; Michael Doctor; Lisa Saiman
Journal:  J Antimicrob Chemother       Date:  2010-04-29       Impact factor: 5.790

6.  Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.

Authors:  L Saiman; Y Chen; S Tabibi; P San Gabriel; J Zhou; Z Liu; L Lai; S Whittier
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

7.  Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis.

Authors:  L Saiman; S Tabibi; T D Starner; P San Gabriel; P L Winokur; H P Jia; P B McCray; B F Tack
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

8.  Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  J L Burns; L Saiman; S Whittier; D Larone; J Krzewinski; Z Liu; S A Marshall; R N Jones
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

9.  Evaluation of the Merlin, Micronaut system for automated antimicrobial susceptibility testing of Pseudomonas aeruginosa and Burkholderia species isolated from cystic fibrosis patients.

Authors:  S Häussler; S Ziesing; G Rademacher; L Hoy; H Weissbrodt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-07-25       Impact factor: 3.267

10.  Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents.

Authors:  Helio S Sader; Thomas R Fritsche; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.